Please contact Sony Tuteja, PharmD, MS at sonyt@pennmedicine.upenn.edu if you are interested in collaborating on pharmacogenomics research projects.
Impact of Pharmacogenetic Variants in the University of Pennsylvania Health System
Principal Investigator: Sony Tuteja, PharmD, MS
The goal of this project is to identify actionable pharmacogenetics variants within the Penn Biobank and develop methods to identify drug-related outcomes in the electronic health record. Learn more about Dr. Sony Tuteja’s Precision Medicine Accelerator Fund Project.
Clinical Implementation of CYP2C19 testing
Investigators: Sony Tuteja, PharmD, MS and Jay Giri, MD, MPH
The goals of this project are to establish CYP2C19 as a clinical test, initiate and create clinical decision support tools within the electronic health record, create a workflow for pharmacogenetic test billing and assess economic impact, and assess the need for provider and patient education. CYP2C19-Clopidogrel testing information.
Assessment of prospective CYP2C19 genotype guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (the ADAPT Study)
Investigators: Sony Tuteja, PharmD, MS and Jay Giri, MD, MPH
The purpose of this study is to determine the clinical impact of CYP2C19 genotyping following percutaneous coronary intervention (PCI). Clinical trials.gov registration: NCT02508116. Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (ADAPT).